Financial Information for Guarantor Subsidiaries and Non-Guarantor Subsidiaries - Supplemental Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions | 12 Months Ended |
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Condensed Financial Statements, Captions [Line Items] | | | |
Net cash (used in) provided by operating activities | $ 546 | $ 346 | $ 507 |
Cash flows from investing activities: | | | |
Capital expenditures | (285) | (391) | (294) |
Distributions of capital from equity investments | 23 | 30 | 34 |
Acquisitions and additions to equity method investments | (1) | (180) | (107) |
Other, principally change in intercompany investing activities | 0 | | |
Increase (Decrease) In Other Operating Assets And Liabilities, Net, Including Proceeds From Asset Sales, Investing Activities | | | 10 |
Payments for (Proceeds from) Other Investing Activities | | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | 0 | (297) | (58) |
Proceeds from Sales of Assets, Investing Activities | | 40 | |
Net cash used in investing activities | (263) | (798) | (415) |
Cash flows from financing activities: | | | |
Payments on long-term debt, net of proceeds | (397) | 238 | (415) |
Net Payments For (Proceeds From) Long-Term Debt | | | (701) |
Payments of debt issuance and deferred financing costs | 35 | 38 | 59 |
Payments on license obligations | (40) | (45) | (53) |
Sale of future revenue | 11 | | |
Net proceeds from the sale of SciPlay common stock | 342 | 0 | 0 |
Payments of deferred SciPlay common stock offering costs | (9) | 0 | 0 |
Net redemptions of common stock under stock-based compensation plans and other | (1) | (21) | (9) |
Other, principally change in intercompany financing activities | 0 | 0 | 0 |
Payments of assumed NYX debt and other acquisitions debt | 0 | (290) | 0 |
Payment of Financing and Stock Issuance Costs | | (38) | (59) |
Net cash (used in) provided by financing activities | (129) | (156) | 580 |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 1 | (6) | 5 |
Increase (decrease) in cash, cash equivalents and restricted cash | 155 | (614) | 677 |
Cash, cash equivalents and restricted cash, beginning of period | 220 | 834 | 157 |
Cash, cash equivalents and restricted cash, end of period | 375 | 220 | 834 |
Reportable Legal Entities | Parent Company | | | |
Condensed Financial Statements, Captions [Line Items] | | | |
Net cash (used in) provided by operating activities | (57) | (221) | (41) |
Cash flows from investing activities: | | | |
Capital expenditures | (22) | (35) | (53) |
Distributions of capital from equity investments | 0 | 0 | 0 |
Acquisitions and additions to equity method investments | 0 | 0 | 0 |
Other, principally change in intercompany investing activities | 0 | | |
Increase (Decrease) In Other Operating Assets And Liabilities, Net, Including Proceeds From Asset Sales, Investing Activities | | | 0 |
Payments for (Proceeds from) Other Investing Activities | | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | | 0 | 0 |
Proceeds from Sales of Assets, Investing Activities | | 0 | |
Net cash used in investing activities | (22) | (35) | |
Cash flows from financing activities: | | | |
Payments on long-term debt, net of proceeds | 0 | 0 | (53) |
Net Payments For (Proceeds From) Long-Term Debt | | | 250 |
Payments of debt issuance and deferred financing costs | 0 | | |
Payments on license obligations | (27) | (43) | (48) |
Sale of future revenue | 0 | | |
Net proceeds from the sale of SciPlay common stock | 0 | | |
Payments of deferred SciPlay common stock offering costs | 0 | | |
Net redemptions of common stock under stock-based compensation plans and other | 7 | (18) | (8) |
Other, principally change in intercompany financing activities | 122 | (342) | 1,100 |
Payments of assumed NYX debt and other acquisitions debt | | 0 | |
Payment of Financing and Stock Issuance Costs | | 0 | 0 |
Net cash (used in) provided by financing activities | 102 | (403) | 794 |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 0 | 0 | 0 |
Increase (decrease) in cash, cash equivalents and restricted cash | 23 | (659) | 700 |
Cash, cash equivalents and restricted cash, beginning of period | 74 | 733 | 33 |
Cash, cash equivalents and restricted cash, end of period | 97 | 74 | 733 |
Reportable Legal Entities | Guarantor Subsidiaries | | | |
Condensed Financial Statements, Captions [Line Items] | | | |
Net cash (used in) provided by operating activities | 109 | 206 | 567 |
Cash flows from investing activities: | | | |
Capital expenditures | (112) | (146) | (129) |
Distributions of capital from equity investments | 0 | 0 | 0 |
Acquisitions and additions to equity method investments | 0 | 0 | 0 |
Other, principally change in intercompany investing activities | 0 | | |
Increase (Decrease) In Other Operating Assets And Liabilities, Net, Including Proceeds From Asset Sales, Investing Activities | | | 8 |
Payments for (Proceeds from) Other Investing Activities | | 0 | 0 |
Payments to Acquire Businesses, Net of Cash Acquired | | (32) | (26) |
Proceeds from Sales of Assets, Investing Activities | | 40 | |
Net cash used in investing activities | (112) | (138) | |
Cash flows from financing activities: | | | |
Payments on long-term debt, net of proceeds | 0 | 0 | (147) |
Net Payments For (Proceeds From) Long-Term Debt | | | 0 |
Payments of debt issuance and deferred financing costs | 0 | | |
Payments on license obligations | (10) | (2) | (5) |
Sale of future revenue | 11 | | |
Net proceeds from the sale of SciPlay common stock | 0 | | |
Payments of deferred SciPlay common stock offering costs | 0 | | |
Net redemptions of common stock under stock-based compensation plans and other | (4) | (3) | (1) |
Other, principally change in intercompany financing activities | 15 | (62) | (411) |
Payments of assumed NYX debt and other acquisitions debt | | (2) | |
Payment of Financing and Stock Issuance Costs | | 0 | 0 |
Net cash (used in) provided by financing activities | 12 | (69) | (417) |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 0 | 0 | 0 |
Increase (decrease) in cash, cash equivalents and restricted cash | 9 | (1) | 3 |
Cash, cash equivalents and restricted cash, beginning of period | 43 | 44 | 41 |
Cash, cash equivalents and restricted cash, end of period | 52 | 43 | 44 |
Reportable Legal Entities | Non-Guarantor Subsidiaries | | | |
Condensed Financial Statements, Captions [Line Items] | | | |
Net cash (used in) provided by operating activities | 320 | 341 | 283 |
Cash flows from investing activities: | | | |
Capital expenditures | (123) | (147) | (81) |
Distributions of capital from equity investments | 23 | 30 | 34 |
Acquisitions and additions to equity method investments | 0 | (178) | (107) |
Other, principally change in intercompany investing activities | 0 | | |
Increase (Decrease) In Other Operating Assets And Liabilities, Net, Including Proceeds From Asset Sales, Investing Activities | | | 2 |
Payments for (Proceeds from) Other Investing Activities | | 0 | 120 |
Payments to Acquire Businesses, Net of Cash Acquired | | (265) | (32) |
Proceeds from Sales of Assets, Investing Activities | | 0 | |
Net cash used in investing activities | (100) | (560) | |
Cash flows from financing activities: | | | |
Payments on long-term debt, net of proceeds | (2) | (8) | (304) |
Net Payments For (Proceeds From) Long-Term Debt | | | 7 |
Payments of debt issuance and deferred financing costs | 1 | | |
Payments on license obligations | (2) | 0 | 0 |
Sale of future revenue | 0 | | |
Net proceeds from the sale of SciPlay common stock | 342 | | |
Payments of deferred SciPlay common stock offering costs | (9) | | |
Net redemptions of common stock under stock-based compensation plans and other | (2) | 0 | 0 |
Other, principally change in intercompany financing activities | (426) | 563 | 0 |
Payments of assumed NYX debt and other acquisitions debt | | (288) | |
Payment of Financing and Stock Issuance Costs | | 0 | 0 |
Net cash (used in) provided by financing activities | (100) | 267 | (7) |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 1 | (6) | 5 |
Increase (decrease) in cash, cash equivalents and restricted cash | 121 | 42 | (23) |
Cash, cash equivalents and restricted cash, beginning of period | 102 | 60 | 83 |
Cash, cash equivalents and restricted cash, end of period | 223 | 102 | 60 |
Reportable Legal Entities | SGI | | | |
Condensed Financial Statements, Captions [Line Items] | | | |
Net cash (used in) provided by operating activities | 173 | 18 | (300) |
Cash flows from investing activities: | | | |
Capital expenditures | (28) | (63) | (31) |
Distributions of capital from equity investments | 0 | 0 | 0 |
Acquisitions and additions to equity method investments | (1) | (2) | 0 |
Other, principally change in intercompany investing activities | (289) | | |
Increase (Decrease) In Other Operating Assets And Liabilities, Net, Including Proceeds From Asset Sales, Investing Activities | | | 0 |
Payments for (Proceeds from) Other Investing Activities | | 159 | 569 |
Payments to Acquire Businesses, Net of Cash Acquired | | 0 | 0 |
Proceeds from Sales of Assets, Investing Activities | | 0 | |
Net cash used in investing activities | 260 | (224) | |
Cash flows from financing activities: | | | |
Payments on long-term debt, net of proceeds | (395) | 246 | (600) |
Net Payments For (Proceeds From) Long-Term Debt | | | (958) |
Payments of debt issuance and deferred financing costs | 34 | | |
Payments on license obligations | (1) | 0 | 0 |
Sale of future revenue | 0 | | |
Net proceeds from the sale of SciPlay common stock | 0 | | |
Payments of deferred SciPlay common stock offering costs | 0 | | |
Net redemptions of common stock under stock-based compensation plans and other | (2) | 0 | 0 |
Other, principally change in intercompany financing activities | 0 | 0 | 0 |
Payments of assumed NYX debt and other acquisitions debt | | 0 | |
Payment of Financing and Stock Issuance Costs | | (38) | (59) |
Net cash (used in) provided by financing activities | (432) | 208 | 899 |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 0 | 0 | 0 |
Increase (decrease) in cash, cash equivalents and restricted cash | 1 | 2 | (1) |
Cash, cash equivalents and restricted cash, beginning of period | 2 | 0 | 1 |
Cash, cash equivalents and restricted cash, end of period | 3 | 2 | 0 |
Eliminating Entries | | | |
Condensed Financial Statements, Captions [Line Items] | | | |
Net cash (used in) provided by operating activities | 1 | 2 | (2) |
Cash flows from investing activities: | | | |
Capital expenditures | 0 | 0 | 0 |
Distributions of capital from equity investments | 0 | 0 | 0 |
Acquisitions and additions to equity method investments | 0 | 0 | 0 |
Other, principally change in intercompany investing activities | 289 | | |
Increase (Decrease) In Other Operating Assets And Liabilities, Net, Including Proceeds From Asset Sales, Investing Activities | | | 0 |
Payments for (Proceeds from) Other Investing Activities | | (159) | (689) |
Payments to Acquire Businesses, Net of Cash Acquired | | 0 | 0 |
Proceeds from Sales of Assets, Investing Activities | | 0 | |
Net cash used in investing activities | (289) | 159 | |
Cash flows from financing activities: | | | |
Payments on long-term debt, net of proceeds | 0 | 0 | 689 |
Net Payments For (Proceeds From) Long-Term Debt | | | 0 |
Payments of debt issuance and deferred financing costs | 0 | | |
Payments on license obligations | 0 | 0 | 0 |
Sale of future revenue | 0 | | |
Net proceeds from the sale of SciPlay common stock | 0 | | |
Payments of deferred SciPlay common stock offering costs | 0 | | |
Net redemptions of common stock under stock-based compensation plans and other | 0 | 0 | 0 |
Other, principally change in intercompany financing activities | 289 | (159) | (689) |
Payments of assumed NYX debt and other acquisitions debt | | 0 | |
Payment of Financing and Stock Issuance Costs | | 0 | 0 |
Net cash (used in) provided by financing activities | 289 | (159) | (689) |
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 0 | 0 | 0 |
Increase (decrease) in cash, cash equivalents and restricted cash | 1 | 2 | (2) |
Cash, cash equivalents and restricted cash, beginning of period | (1) | (3) | (1) |
Cash, cash equivalents and restricted cash, end of period | $ 0 | $ (1) | $ (3) |